A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT

Inclusion Criteria

• •1. Patients with CAEBV or EBV-HLH who are eligible for allogeneic hematopoietic stem cell transplantation meet one of the following criteria:
• •①EBV-DNA (PBMC or plasma) was still more than 103 before transplantation；②Positive for Cerebrospinal fluid EBV-DNA；
• •③Abnormal phenotypic lymphocytes could still be detected in bone marrow immunotyping；
• •④Measurable EBV-related lesions on imaging；
• •2. ≤65 years，ECOG :0-2；
• •3. Cardiac EF≥40%, creatinine clearance ≥50%; aminotransferase（ALT/AST）\<200U/L。；
• •4. In patients with HLH, HLH efficacy ≥Partial Response after prior treatment is required；
• •5. Estimated survival time is longer than three months；
• •6. Agree to sign the Informed Consent Form。